Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CELLULAR GOODS PLC Remuneration Information 2023

Jun 9, 2023

5058_def-14a_2023-06-09_214365ce-1024-46ff-aefd-18906a288317.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information /*<![CDATA[*/ /**/ /**/ /**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .al{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.al{}p.bo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bm{font-size:11.0pt;font-family:"Times New Roman","serif";color:black}p.bp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:center}p.bq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.br{font-size:11.0pt;color:black}span.bs{font-size:11.0pt; color:black}span.bt{font-size: 11.0pt;color:black}span.bu{font-size:11.0pt} span.bf{color:black}span.bj{font-size:11.0pt;color:black}p.bv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height:13.0pt}table.bw{margin-left:-10.8pt;border-collapse:collapse}td.ba{width:203.7pt;border:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.bx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-bottom:8.0pt;text-align:justify;line-height: 106%}span.bc{font-size:11.0pt;line-height:106%; font-family:"Times New Roman","serif"}td.ay{width:203.7pt;border:solid black 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}span.az{font-size:11.0pt;line-height:106%;font-family: "Times New Roman","serif"}td.ax{width:203.7pt;border:solid black 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt} td.av{width:203.7pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.aw{font-size:11.0pt;line-height:106%; font-family:"Times New Roman","serif";color:#0D0D0D}p.by{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify;line-height:13.0pt}span.au{font-size:11.0pt;font-family:"Times New Roman","serif"; color:#0D0D0D}span.as{font-size:11.0pt;line-height:106%;font-family: "Times New Roman","serif";color:#0D0D0D}span.ar{font-size:11.0pt;line-height:106%;font-family:"Times New Roman","serif"}p.bz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:13.0pt}span.ap{font-size:11.0pt;font-family:"Times New Roman","serif"; color:black}span.an{font-size:11.0pt;font-family:"Times New Roman","serif"}span.am{font-size:11.0pt; font-family:"Times New Roman","serif";color:#0563C1} p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .al{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/

RNS Number : 1766C

Cellular Goods PLC

09 June 2023

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press release

9 June 2023

Cellular Goods PLC

("Cellular Goods" or "the Company")

Grant of Warrants

Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, announces that it has granted a total of 3,000,000 warrants to subscribe for new ordinary shares of £0.001 each ("Warrants") to members of its Advisory Board. The Warrants are exercisable at 1.5 pence per ordinary share.

One third of the warrants will vest on 8 June 2024 with the remaining two thirds vesting in 24 equal monthly instalments thereafter. The Warrants have an exercise period from the date of grant to 8 June 2028.

Following the issue of the Warrants, the Company has a total of 12,500,000 warrants in issue.  

For further information please contact:

Cellular Goods
Darcy Taylor

Chairman and interim CEO

Neil Thapar

Investor Relations
via Tancredi +44 207 887 7633

+44 787 645 5323
First Sentinel Corporate Finance
Corporate Broker & Advisor

Brian Stockbridge
+44 7876 888 011
Novum Securities
Corporate Broker

Colin Rowbury

Jon Belliss
+44 207 399 9427
Tancredi Intelligent Communication
Media Relations

Helen Humphrey

Charlie Hobbs

[email protected]
+44 744 922 6720

+44 789 755 7112

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEVVLFBXQLLBBL